Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: Comparison with conventional structural analyses

✍ Scribed by Mitsuhiro Tada; Richard D. Iggo; Francois Waridel; Michimasa Nozaki; Ryoji Matsumoto; Yutaka Sawamura; Yumiko Shinohe; Jun Ikeda; Hiroshi Abe

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 282 KB
• Volume: 18
• Category: Article
• ISSN: 0899-1987
• DOI: 10.1002/(sici)1098-2744(199703)18:3<171::aid-mc6>3.0.co;2-i

✦ Synopsis

We previously reported clonal expansion of p53 mutations in malignant astrocytic tumors detected with a yeast p53 functional assay that measures mutant p53 alleles quantitatively and loss of p53 transcriptional competence qualitatively (Tada et al., Int J Cancer 67:447-450, 1996). This method selectively detects inactivating mutations and is relatively insensitive to contamination of tumor samples with normal tissue. To determine whether the mutation frequency and spectrum detected in this way differ from those seen with conventional techniques, 54 malignant astrocytomas were tested with the yeast assay, and the abnormalities detected were characterized by DNA sequencing. Inactivating p53 mutations were found in 67% of anaplastic astrocytomas and 41% of glioblastomas. Overall, mutations were found in 48% of tumors, compared with only 29% in previous studies (P < 0.005), a difference that probably reflects the greater sensitivity of the yeast assay than of conventional techniques. The frequency of mutations in anaplastic astrocytomas (in our study plus published studies) was significantly higher than in glioblastomas (39% vs 29%; P < 0.05). This suggests that acquisition of p53 mutations is not rate limiting for progression to glioblastoma and that many glioblastomas develop by p53-independent pathways. Sequencing of mutant p53 cDNAs rescued from yeast showed that the mutation spectrum for functionally inactive mutants was nearly identical to the spectra from previous studies on structural mutants, indicating that transcriptional activity is the critical biological target of p53 mutation in malignant astrocytomas.